Galectin Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.745; its P/E ratio is -4.63; Galectin Therapeutics is scheduled to report earnings on May 13, 2024, and the estimated EPS forecast is $-0.16. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	$ -9.15M	$ -9.59M	$ -8.46M	$ -11.07M	$ -10.36M
EBITDA	$ -9.14M	$ -9.59M	$ -8.48M	$ -11.04M	$ -10.35M
Net Income Common Stockholders	$ -10.06M	$ -14.04M	$ -9.18M	$ -11.53M	$ -10.70M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 25.66M	$ 20.36M	$ 17.97M	$ 17.80M	$ 18.59M
Total Assets	$ 28.20M	$ 22.16M	$ 20.08M	$ 20.23M	$ 21.29M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ -25.66M	$ -20.36M	$ -17.97M	$ -17.80M	$ -18.59M
Total Liabilities	$ 88.44M	$ 73.04M	$ 72.93M	$ 64.59M	$ 53.48M
Stockholders Equity	$ -61.96M	$ -52.60M	$ -52.85M	$ -44.37M	$ -33.92M
Cash Flow	-
Free Cash Flow	$ -4.70M	$ -7.64M	$ -9.83M	$ -10.79M	$ -7.24M
Operating Cash Flow	$ -4.70M	$ -7.64M	$ -9.83M	$ -10.79M	$ -7.24M
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	$ 10.00M	$ 10.03M	$ 10.00M	$ 10.00M	$ 10.00M

Currency in USD

Galectin Therapeutics Earnings and Revenue History

Income Statement >

Galectin Therapeutics Debt to Assets

Balance Sheet >

Galectin Therapeutics Cash Flow

Cash Flow >

Galectin Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing